We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Theranos Hit With 483s Over Documentation, QMS Problems

Theranos Hit With 483s Over Documentation, QMS Problems

November 27, 2015

Theranos, a hot startup that recently received media scrutiny regarding its testing system, has been hit with two 483s, one of which takes the company to task for shipping an uncleared device.

During an Aug. 25 to Sept. 16 inspection of Theranos facilities in Newark, Calif., an FDA representative determined that the company improperly identified its Capillary Tube Nanotainer, a blood specimen collection device, as Class I exempt. It should be listed as Class II, according to the 483.

In addition, the FDA dings the company for not having a formal unit in place for receiving, reviewing and evaluating complaints. Its two written procedures don’t accurately describe the entire complaint handling procedure. Further, its written procedures do not match those verbally described during the inspection.

The investigator also observed that complaints involving possible failure of a device were not investigated properly. It cites a complaint that says parts of a component were too opaque to see clotting clearly. According to the 483, the company neither identified nor investigated this as a complaint. It also did not confirm whether it needed to file an MDR.

The facility also is taken to task for not documenting corrective and preventive action activities. It made several corrections to its quality management system procedures without documenting and investigating the causes of nonconformities.

“For example, during this inspection, you were unable to produce documented supplier qualifications, and you corrected the deficiency by assembling the required supplier qualification documents for your suppliers,” the 483 stated. The company undertook this action, however, without opening a CAPA to determine the possible cause for not having supplier qualification documentation. Further, it failed to determine whether suppliers had met quality requirements for the entire time they had done business with Theranos.

The company also is dinged for failure to: Document software validation activities, establish records of acceptable suppliers, have procedures for device history records or perform quality audits.

In a statement, Theranos says it has been building quality systems. “Theranos had voluntarily begun transitioning from the CLIA laboratory quality systems to FDA quality systems throughout 2014,” the statement adds.

Palo Alto 483

The company also received a 483 for an inspection at its Palo Alto facility that is heavily redacted. It hits the company over its design validation, which didn’t ensure the device conformed to defined user needs and intended uses. In addition, the design was not validated under actual or simulated use conditions, neither design input requirements nor results of the design risk analysis were adequately documented and documents were not reviewed or approved by a designated individual prior to issuance.

Word of the 483s came days after news reports questioned whether Theranos’ device, dubbed Edison, could be used in all of the tests the company claimed. It also questioned the test’s accuracy.

The company hit back against the allegations. “We are confident in the reliability of our tests, because we comprehensively validate the accuracy of every test we run,” the company says.

Whether you need to convince the FDA to accept a predicate device in a simple 510(k) filing, make design changes or implement UDI across a family of high-risk implantable devices, there’s one thing all regulatory professionals need — the most up-to-date, latest FDA regulations available. Get out bestselling Guide to FDA Medical Device Regulations today!

Medical Devices Regulatory Affairs

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing